This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
SYNLAB Inkomsten in het verleden
We zijn nog bezig met het verwerken van het laatste winstrapport van dit bedrijf
Verleden criteriumcontroles 2/6
SYNLAB's earnings have been declining at an average annual rate of -9%, while the Healthcare industry saw earnings growing at 3.6% annually. Revenues have been declining at an average rate of 11.5% per year. SYNLAB's return on equity is 3.8%, and it has net margins of 3.4%.
Belangrijke informatie
-9.0%
Groei van de winst
-14.1%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 15.7% |
| Inkomstengroei | -11.5% |
| Rendement op eigen vermogen | 3.8% |
| Nettomarge | 3.4% |
| Volgende winstupdate | 07 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger
Dec 15
Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)
Sep 10SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 14SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market
May 29SYNLAB (FRA:SYAB) Is Investing Its Capital With Increasing Efficiency
May 20Are Investors Undervaluing SYNLAB AG (FRA:SYAB) By 25%?
Sep 26Shareholders Will Be Pleased With The Quality of SYNLAB's (FRA:SYAB) Earnings
Aug 22Opbrengsten en kosten
Hoe SYNLAB geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 24 | 2,615 | 89 | 1,159 | 0 |
| 31 Dec 23 | 2,635 | 92 | 1,163 | 0 |
| 30 Sep 23 | 2,691 | 129 | 1,191 | 0 |
| 30 Jun 23 | 2,772 | 69 | 1,197 | 0 |
| 31 Mar 23 | 2,892 | -37 | 1,213 | 0 |
| 31 Dec 22 | 3,251 | 151 | 1,231 | 0 |
| 30 Sep 22 | 3,542 | 345 | 1,264 | 0 |
| 30 Jun 22 | 3,693 | 404 | 1,265 | 0 |
| 31 Mar 22 | 3,888 | 653 | 1,247 | 0 |
| 31 Dec 21 | 3,765 | 608 | 1,209 | 0 |
| 30 Sep 21 | 3,703 | 591 | 1,155 | 0 |
| 30 Jun 21 | 3,561 | 385 | 1,119 | 0 |
| 31 Mar 21 | 3,080 | 225 | 1,026 | 0 |
| 31 Dec 20 | 2,621 | 36 | 962 | 0 |
| 31 Dec 19 | 1,906 | -122 | 817 | 0 |
| 31 Dec 18 | 1,808 | -51 | 776 | 0 |
| 31 Dec 17 | 1,817 | -166 | 870 | 0 |
| 31 Dec 16 | 1,570 | -230 | 689 | 0 |
| 31 Dec 15 | 845 | -169 | 401 | 0 |
Kwaliteitswinsten: SYAB has a large one-off gain of €84.4M impacting its last 12 months of financial results to 31st March, 2024.
Groeiende winstmarge: SYAB became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SYAB has become profitable over the past 5 years, growing earnings by -9% per year.
Versnelling van de groei: SYAB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: SYAB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (30.9%).
Rendement op eigen vermogen
Hoge ROE: SYAB's Return on Equity (3.8%) is considered low.